Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 3, 2012, Pages 497-505

  Tarning, J ^a,b   Zongo, I ^c   Some F A ^c   Rouamba, N ^c   Parikh, S ^d   Rosenthal, P J ^d   Hanpithakpong, W ^a   Jongrak, N ^a   Day, N P J ^a,b   White, N J ^a,b   Nosten, F ^a,b,e   Ouedraogo, J B ^c   Lindegardh, N ^a,b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c Centre National de la Recherche Scientifique et Technologique   (Burkina Faso)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SHOKLO MALARIA RESEARCH UNIT   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROARTEMISININ PLUS PIPERAQUINE;

AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; BURKINA FASO; CHILD; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PEDIATRICS; PLASMA CONCENTRATION-TIME CURVE; POPULATION MODEL; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT INFECTION; SCHOOL CHILD; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ARTEMISININS; BODY WEIGHT; BURKINA FASO; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; QUINOLINES;

EID: 84857233900     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.254     Document Type: Article

References (36)

1. Pashynska, V.A., Van den Heuvel, H., Claeys, M. & Kosevich, M.V. Characterization of noncovalent complexes of antimalarial agents of the artemisinin-type and FE(III)-heme by electrospray mass spectrometry and collisional activation tandem mass spectrometry. J. Am. Soc. Mass Spectrom. 15, 1181-1190 (2004). (Pubitemid 38970062)
2. World HealtHorganization. Guidelines for the treatment of malaria (2010).
3. Zwang, J. et al. Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS ONE 4, e6358 (2009).
4. Nankabirwa, J. et al. Efficacy, safety, and tolerability of three regimens for prevention of malaria: a randomized, placebo-controlled trial in Ugandan schoolchildren. PLoS ONE 5, e13438 (2010).
5. Bojang, K.A. et al. Prevention of the recurrence of anaemia in Gambian children following discharge from hospital. PLoS ONE 5, e11227 (2010).
6. Tarning, J. et al. Characterization of human urinary metabolites of the antimalarial piperaquine. Drug Metab. Dispos. 34, 2011-2019 (2006). (Pubitemid 44837762)
7. Tarning, J., Lindegardh, N., Sandberg, S., Day, N.J., White, N.J. & Ashton, M. Pharmacokinetics and metabolism of the antimalarial piperaquine after intravenous and oral single doses to the rat. J. Pharm. Sci. 97, 3400-3410 (2008).
8. Hung, T.Y. et al. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br. J. Clin. Pharmacol. 57, 253-262 (2004).
9. Tarning, J. et al. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob. Agents Chemother. 52, 1052-1061 (2008). (Pubitemid 351358388)
10. Karunajeewa, H.A. et al. Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. Antimicrob. Agents Chemother. 52, 237-243 (2008).
11. Smithuis, F. et al. Efficacy and effectiveness of dihydroartemisinin- piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet 367, 2075-2085 (2006). (Pubitemid 43949291)
12. White, N.J., Stepniewska, K., Barnes, K., Price, R.N. & Simpson, J. Simplified antimalarial therapeutic monitoring: using the day-7 drug level? Trends Parasitol. 24, 159-163 (2008).
13. Price, R.N. et al. Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob. Agents Chemother. 51, 4090-4097 (2007). (Pubitemid 350057809)
14. Savic, R.M., Jonker, D.M., Kerbusch, T. & Karlsson, M.O. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J. Pharmacokinet. Pharmacodyn. 34, 711-726 (2007). (Pubitemid 47477040)
15. Savic, R.M. & Karlsson, M.O. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 11, 558-569 (2009).
16. Bergstrand, M., Hooker, A.C., Wallin, J.E. & Karlsson, M.O. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 13, 143-151 (2011).
17. Sigma-tau: Application for Inclusion of Dihydroartemisinin Plus Piperaquine (DHA/PPQ) Fixed Dose Combination Tablets in the 17th edition of the WHO Model Lists of Essential Medicines 〈http://www.who.int/selection- medicines/committees/expert/18/applications/D-Piperaquine.pdf〉.
18. Zongo, I. et al. Randomized comparison of amodiaquine plus sulfadoxinepyrimethamine, artemether-lumefantrine, and dihydroartemisininpiperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin. Infect. Dis. 45, 1453-1461 (2007). (Pubitemid 351411875)
19. Cisse, B. et al. Randomized trial of piperaquine with sulfadoxinepyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children. PLoS ONE 4, e7164 (2009).
20. Douglas, N.M. et al. Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin. Infect. Dis. 52, 612-620 (2011).
21. Awab, G.R. et al. Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial. Malar. J. 9, 105 (2010).
22. Hai, T.N., Hietala, S.F., Van Huong, N. & Ashton, M. The influence of food on the pharmacokinetics of piperaquine in healthy Vietnamese volunteers. Acta Trop. 107, 145-149 (2008).
23. Annerberg, A. et al. A small amount of fat does not affect piperaquine exposure in patients with malaria. Antimicrob. Agents Chemother. 55, 3971-3976 (2011).
24. Sim, I.K., Davis, T.M. & Ilett, K.F. Effects of a high-fat meal on the relative oral bioavailability of piperaquine. Antimicrob. Agents Chemother. 49, 2407-2411 (2005). (Pubitemid 40734473)
25. Nguyen, T.C., Nguyen, N.Q., Nguyen, X.T., Bui, D., Travers, T. & Edstein, M.D. Pharmacokinetics of the antimalarial drug piperaquine in healthy Vietnamese subjects. Am. J. Trop. Med. Hyg. 79, 620-623 (2008).
26. Rhammar, D., Hai, T.N., Friberg Hietala, S., Van Huong, N. & Ashton, M. Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects. Eur. J. Clin. Pharmacol. 62, 335-341 (2006).
27. Ashley, E.A. et al. Comparison of plasma, venous and capillary blood levels of piperaquine in patients with uncomplicated falciparum malaria. Eur. J. Clin. Pharmacol. 66, 705-712 (2010).
28. Nguyen, D.V. et al. Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam. Antimicrob. Agents Chemother. 53, 3534-3537 (2009).
29. Barnes, K.I., Little, F., Smith, P.J., Evans, A., Watkins, W.M. & White, N.J. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin. Pharmacol. Ther. 80, 582-596 (2006). (Pubitemid 44920218)
30. Myint, H.Y., Ashley, E.A., Day, N.P., Nosten, F. & White, N.J. Efficacy and safety of dihydroartemisinin-piperaquine. Trans. R. Soc. Trop. Med. Hyg. 101, 858-866 (2007). (Pubitemid 47091464)
31. Ashley, E.A. et al. Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. J. Infect. Dis. 190, 1773-1782 (2004). (Pubitemid 39487822)
32. ICH Expert Working Group. ICH Harmonised Tripartite Guideline, Text on Validation of Analytical Procedures (1994).
33. Kongpatanakul, S. et al. Evaluation of the safety and relative bioavailability of a new dihydroartemisinin tablet formulation in healthy Thai volunteers. Trans. R. Soc. Trop. Med. Hyg. 101, 972-979 (2007). (Pubitemid 47317246)
34. Kongpatanakul, S., Chatsiricharoenkul, S., Khuhapinant, A., Atipas, S. & Kaewkungwal, J. Comparative study of dihydroartemisinin and artesunate safety in healthy Thai volunteers. Int. J. Clin. Pharmacol. Ther. 47, 579-586 (2009).
35. Lindegardh, N., Annerberg, A., White, N.J. & Day, N.P. Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of piperaquine in plasma stable isotope labeled internal standard does not always compensate for matrix effects. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 862, 227-236 (2008).
36. Beal, S.L., Boeckman, A.J. & Sheiner, L.B. NONMEM user's guides. NONMEM Project Group, University of California at San Francisco (1992).